Key result
Diabetes and stent size show no significant association with MACE after PCI.
Why the study?
The relationship between different stent sizes and clinical outcomes after PCI in patients with diabetes treated with DES and DAPT was unclear.
Does diabetes mellitus or stent size impact the incidence of MACE in patients with stable coronary artery disease undergoing elective PCI with DES?
Cohort (n=1,630)
Does diabetes mellitus or stent size impact the incidence of MACE in patients with stable coronary artery disease undergoing elective PCI with DES?
In patients undergoing elective PCI with DES, diabetes did not significantly influence long-term MACE when managed with long-term DAPT, and stent size did not affect outcomes in diabetic patients.
Stent size was unassociated with MACE in diabetics; observational data leave open whether dimensions affect outcomes and require prospective confirmation.
Background: This study aimed to investigate the possible relationship between different stent sizes and clinical outcomes after percutaneous coronary intervention (PCI) in patients with diabetes treated with drug-eluting stents (DESs) and dual antiplatelet therapy (DAPT). Methods: Patients with stable coronary artery disease undergoing elective PCI with the DES were entered into a retrospective cohort between 2003 and 2019. Major adverse cardiac events (MACE), defined as the combined endpoint of revascularization, myocardial infarction, and cardiovascular death, were recorded. The participants were categorized according to the stent size: 27 mm for length and 3 mm for diameter. DAPT (aspirin and clopidogrel) was used for at least 2 years for diabetics and 1 year for nondiabetics. The median duration of follow-up was 74.7 months. Results: Out of 1630 participants, 29.0% had diabetes. The diabetics constituted 37.8% of those with MACE. The mean diameter of the stents in the diabetics and nondiabetics was 2.81±0.29 mm and 2.90±0.35 mm, respectively (P>0.05). The mean stent length was 19.48±7.58 mm and 18.92±6.64 mm in the diabetics and nondiabetics, respectively (P>0.05). After adjustments for confounding variables, MACE was not significantly different between the patients with and without diabetes. Although MACE incidence was not affected by stent dimensions in the patients with diabetes, the nondiabetic patients implanted with a stent length exceeding 27 mm experienced MACE less frequently. Conclusion: Diabetes did not influence MACE in our population. Additionally, stents of different sizes were not associated with MACE in patients with diabetes. We propose that using the DES supplemented by long-term DAPT and tight control of glycemic status after PCI could decrease the adverse consequences of diabetes.
No takes yet. Share an insight, caveat, or question.
Zibaeenezhad et al. (2023) conducted a cohort in Stable coronary artery disease undergoing elective PCI (n=1,630). Diabetes Mellitus and stent size vs. Nondiabetics and smaller stent sizes was evaluated on Major adverse cardiac events (MACE: revascularization, myocardial infarction, and cardiovascular death). Diabetes did not significantly influence the incidence of major adverse cardiac events after PCI, nor were different stent sizes associated with MACE in diabetic patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: